Renal Cancer - Results from #1780

Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma. November 25, 2021

Active Surveillance of Renal Masses: The Role of Radiology. November 25, 2021

Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma. November 24, 2021

Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. November 24, 2021

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial. November 23, 2021

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. November 23, 2021

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. November 23, 2021

Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. November 22, 2021

Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. November 22, 2021

Impact of positive vascular margins status after surgical resection of non-metastatic renal cell carcinoma with caval tumour thrombus: a propensity score multicentre study. November 19, 2021

Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action. November 19, 2021

FDA Approves Merck’s Pembrolizumab as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery November 18, 2021

Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma. November 18, 2021

Predictive Impact of Early Changes in Serum C-Reactive Protein Levels in Nivolumab Plus Ipilimumab Therapy for Metastatic Renal Cell Carcinoma. November 18, 2021

Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy. November 17, 2021

Kidney tumor diffusion-weighted magnetic resonance imaging derived ADC histogram parameters combined with patient characteristics and tumor volume to discriminate oncocytoma from renal cell carcinoma. November 17, 2021

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. November 16, 2021

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. November 16, 2021

The The Prognosis and Immune Microenvironment Related Factor Interleukin-23 in Clear Cell Renal Cell Carcinoma: A Radiological Investigation. November 15, 2021

[Synchronous oligometastatic renal cell carcinoma-what is the role of surgery?] November 15, 2021

Page 90 of 457